Literature DB >> 30361253

Compassionate use of delamanid in combination with bedaquiline for the treatment of multidrug-resistant tuberculosis.

Jeffrey Hafkin1, Norbert Hittel2, Alexandra Martin2, Rajesh Gupta1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30361253     DOI： 10.1183/13993003.01154-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  5 in total

1.  QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.

Authors:  Kelly E Dooley; Susan L Rosenkranz; Francesca Conradie; Laura Moran; Richard Hafner; Florian von Groote-Bidlingmaier; Javier R Lama; Justin Shenje; Jorge De Los Rios; Kyla Comins; Joel Morganroth; Andreas H Diacon; Yoninah S Cramer; Kathleen Donahue; Gary Maartens
Journal:  Lancet Infect Dis       Date:  2021-02-12       Impact factor: 71.421

2.  Superior Efficacy of a Bedaquiline, Delamanid, and Linezolid Combination Regimen in a Mouse Tuberculosis Model.

Authors:  Elise D Pieterman; Lina Keutzer; Aart van der Meijden; Sanne van den Berg; Han Wang; Matthew D Zimmerman; Ulrika S H Simonsson; Hannelore I Bax; Jurriaan E M de Steenwinkel
Journal:  J Infect Dis       Date:  2021-09-17       Impact factor: 7.759

3.  Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis.

Authors:  Lénaïg Tanneau; Elin M Svensson; Stefaan Rossenu; Mats O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-10-22

4.  Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens.

Authors:  Lénaïg Tanneau; Mats O Karlsson; Susan L Rosenkranz; Yoninah S Cramer; Justin Shenje; Caryn M Upton; Joel Morganroth; Andreas H Diacon; Gary Maartens; Kelly E Dooley; Elin M Svensson
Journal:  Clin Pharmacol Ther       Date:  2022-07-13       Impact factor: 6.903

5.  Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.

Authors:  Helena Huerga; Uzma Khan; Mathieu Bastard; Carole D Mitnick; Nathalie Lachenal; Palwasha Y Khan; Kwonjune J Seung; Nara Melikyan; Saman Ahmed; Michael L Rich; Francis Varaine; Elna Osso; Makhmujan Rashitov; Naseem Salahuddin; Gocha Salia; Epifanio Sánchez; Armine Serobyan; Muhammad Rafi Siddiqui; Dri Grium Tefera; Dmitry Vetushko; Lusine Yeghiazaryan; David Holtzman; Shirajul Islam; Andargachew Kumsa; Gamarly Jacques Leblanc; Olga Leonovich; Shahid Mamsa; Mohammad Manzur-Ul-Alam; Zaw Myint; Shrivani Padayachee; Molly F Franke; Catherine Hewison
Journal:  Clin Infect Dis       Date:  2022-10-12       Impact factor: 20.999
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.